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                            INTRODUCTION
Tuberculosis remains a world-wide public health problem
 
despite the fact that the causative organism was discovered more than
 
100 years ago and highly effective drugs and vaccine are available 
making tuberculosis a preventable and curable disease.1
India accounts for nearly one-third of the global burden of 
tuberculosis. Every year approximately 18 lakh persons develop 
tuberculosis of which about 8 lakh are new smear positive highly 
infectious cases and about 4.17 lakh people die of tuberculosis every 
year, 1 person dies every minute and about 1000 people die every day.2
                    The obstacles to success include poor patient compliance, 
high cost of medicines, drug resistance, insufficient duration, irregular 
therapy and last but not the least Drug-Induced Hepatitis(DIH).
DIH is the most unwanted adverse effect of Anti 
Tuberculous 
Treatment  (ATT). Unfortunately almost all the chemotherapeutic agents 
used in tuberculosis cause hepatotoxicity by single or multiple 
mechanisms.
The absence of overt jaundice, the degree of subclinical 
hepatotoxicity has to be determined by monitoring the biochemical 
changes using the Liver Function Tests(LFT).
              Reports available from studies conducted to assess the 
hepatotoxicity of Short Course Chemotherapy(SCC) regimens from 
western as  well as many of the Indian studies suggests a low incidence 
of hepatitis. But a few of the Indian studies have shown a high incidence 
of hepatitis due to short course chemotherapeutic regimens.
In view of these variable reports on incidence of drug 
induced hepatotoxicity during SCC, a prospective study was undertaken 
on 108 patients with pulmonary tuberculosis receiving short course 
chemotherapy. In these patients LFT was monitored for a period of 6 
months.
                            AIMS OF THE STUDY
1. To evaluate the incidence of drug induced hepatotoxicity 
     in proved cases of pulmonary tuberculosis in patients on             
        
          short term regimen of anti-tuberculous therapy in 
        
          coimbatore locality.                                         
2. To study about the predisposing factors for drug induced
     hepatotoxicity. 
3.  To study and evaluate the clinical and histopathological
     features of drug induced hepatotoxicity. 
REVIEW OF LITERATURE
DEFINITION:
Tuberculosis is a bacterial infection caused by the acid-fast 
bacilli Mycobacterium tuberculosis. The principle lesions are usually in 
the lungs. Other organs like lymph nodes, intestines, kidney, bone, 
meninges are also involved through dissemination. The portal of entry of 
this organism is almost exclusively through the lungs (droplet infection 
from infected person) except in bovine tuberculosis in which the portal of 
entry is oral.
TB affects human beings in two forms;
1.Primary infection-  in which tubercle bacilli invade the host that has no 
                                 specific immunity 
2. Secondary form[ Re-infection or Adult tuberculosis ]   
- in which the bacilli produce the disease in the 
     phase of specific immunity.
IMMUNITY : 
Tuberculosis has both natural & acquired immunity.
NATURAL IMMUNITY :
                   Members of Caucasian and Mongolian races appear to have 
distinct natural resistance to tuberculosis and it is this ability to develop 
an immune response to infection that enables the host to survive and to 
recover from the primary infection.
ACQUIRED IMMUNITY :
                    Tuberculosis sensitive individuals are quite regularly 
resistant to re-infection and are able to localize the disease readily. 
Reactivation of infection even years after an episode of tuberculosis 
infection which has been successfully handled by the body is a very 
puzzling aspect.
Tuberculous hyper-sensitivity :
                        Hypersensitivity is to the protein derivative of the bacilli. 
Tuberculin hypersensitivity probably indicates the presence of living 
bacilli within the subject whether the lesion in which they lie is active or 
not is sometimes difficult to determine with certainity.
                              PATHOGENESIS
              This is determined by distinctive features of the bacilli and host 
factors. Tubercle bacillus has three important features which distinguish 
it from most other pathogens and also determines the course of the 
disease. These are
1. Slow generation time
2. High lipid content of the 
bacillus
3. Lack of either exotoxin or 
endotoxin.
The hallmark of TB lesion is caseating necrosis with varying 
degrees of exudation, Langerhan giant cells, tubercle formation and 
fibrosis. 3
History of tuberculosis 
                The contagious nature of this infectious disease was recognized 
by Aristotle. Hippocrates conferred the name phthysis. 
 Koch(1882)identified the organism and elaborated the criteria by which 
one could decide upon the connection between a micro organism and the 
disease process (Koch’s postulates)
Pharmacotherapy of tuberculosis 
       For a longtime, the standard duration of tuberculosis chemotherapy 
was 18 months. In 1972, Wallacefox and his colleagues from British 
medical council showed that the addition of rifampicin , pyrazinamide to 
regimens containing isoniazid made it possible to reduce the duration of 
treatment.
                  Advantages of short course chemotherapy are rapid 
bacteriological conversion ,lower failure rates, better patient compliance 
and reduction in the frequency of emergence of drug resistant bacilli. The 
only disadvantage is high cost of short term chemotherapy.
   
                  There are now a number of short course regimens of six 
months duration that are highly effective, of low toxicity and well 
tolerated. The regimens used in Directly Observed Therapy-Short course 
[DOTS]   in Revised National Tuberculosis Control Program [RNTCP] in 
India are given below.(4)
       
TREATMENT REGIMENS 
   
Table 1.Catagories of patients in RNTCP
Category of
Treatment
Type of Patient Regimen*
Category I 1. New Sputum Positive
2. Seriously ill – Sputum
    smear Negative
3. Seriously ill – Extra
    pulmonary**
2(HRZE)3+4(HR)3
Category II 1. Sputum smear positive
    Relapse*** 
2. Sputum smear positive
    Failure.***,#
3. Sputum smear positive
    treatment after default
2(HRZES)3+1(HRZE)3
+5(HRE)3
Category III 1. Sputum smear
    negative not seriously
    ill
2. Extra pulmonary 
     not seriously ill.
2(HRZ)3+4(HR)3
     * -The numbers before the letters refers to the number of months of 
treatment. The subscript after the letters refers to the number of doses 
per week. H: Isoniazid (600mg), R: Rifampicin (450mg), Z 
:pyrazinamide 
(1500mg),E :Ethambutol(1200mg),S :Streptomycin(750mg).patients who 
weigh more than 60 Kg receive additional rifampicin 150mg.patients 
more than 50 years old receive streptomycin (500mg). Patients in 
categories Ist  and IInd, who have a positive sputum smear at the end of 
the initial intensive phase, receive an additional month of intensive 
phase treatment.  
        
       
** -Examples of seriously ill extra pulmonary TB cases are meningitis, 
disseminated TB, tuberculous pericarditis, peritonitis, bilateral or 
extensive pleurisy, spinal TB with neurological complications and 
intestinal and genito urinary –TB.  
           
*** In rare and exceptional cases, patients who are sputum smear 
negative or who have extra pulmonary disease can have relapse or 
Failure. This diagnosis should be supported by culture or histological 
evidence of current, active tuberculosis. In these cases, the patient 
should be categorized as other and given category II Treatment.
 # -  Any patient treated with category I  and category III  who has a 
positive smear at 5, 6 or 7months of treatment should be considered as 
failure and started on category II  treatment afresh.
         
CLASSIFICATION
          
         Drugs used to treat tuberculosis have been classified into first line 
and second line agents 4.First line essential anti tuberculosis agents are 
the most effective and are a necessary component of any short-course 
therapeutic regimens. The three drugs in this category are rifampicin, 
isoniazid  and pyrazinamide. The first line supplemental agents, which 
are highly effective and infrequently toxic include ethambutol and 
streptomycin .Favorable  experience in patients with tuberculosis 
resistant to first line essential drugs suggests that rifabutin and the 
fluroquinolones ciprofloxacin and levofloxacin are important additions to 
multidrug anti- tuberculosis regimens as first line supplemental drugs.
         Second line anti tuberculous agents are clinically much less 
effective than first line agents and elicit severe reactions much more 
frequently. These drugs are rarely used in therapy. The older agents 
include para-aminosalicilic acid (PAS) 
thiozinamide,cycloserine,amikacin 
and capromycin. Newer anti-tuberculous drugs, which have not yet been 
placed in the above categories, include rifapentine, 8 -
methoxyfluroquinolones  gatifloxation and moxifloxacin.
The properties of commonly used anti-tuberculous drugs are given 
below 5
SIDE EFFECTS OF COMMONLY USED ANTI 
TUBERCULOUS AGENTS
Table 2. SIDE EFFECTS OF COMMONLY USED ANTI 
TUBERCULOUS    AGENTS 5,6,7
1. Isoniazid Common
             Rare-
Anorexia, nausea, vomiting, fever,
skin rashes, peripheral neuropathy.
Hepatitis, Vertigo, convulsions, optic
neuritis and atrophy, psychiatric 
disturbance, haemolytic anemia, 
aplastic anemia, dermal reactions 
including pellagra, purpura and lupoid 
syndrome, gynaecomastia, 
hyperglycemia arthralgia
2.Rifampicin Common
Rare 
Orange red discoloration of urine, 
anorexia nausea, vomiting, diarrhea, 
skin rashes.
Flu like syndromes, Hepatitis Dyspnea, 
hypotension, Addisonian crisis, 
menstrual disturbances, muscular 
weakness, pseudomembranous colitis.
3. Pyrazinamide Common
Uncommon
Rare
Anorexia, nausea, vomiting, fever.
Hepatitis, urticaria, Skin rash, 
arthralgia.
Sideroblastic anaemia, photosensiti
zation, gout, dysuria, aggravation of 
peptic ulcer.
4. Ethambutol Uncommon
Rare
Optic neuritis, arthralgia
Hepatitis, interstitial nephritis. 
Cutaneous hypersensitivity paraesthesia 
of extremities.
5. Streptomycin Uncommon
Rare
Vertigo, tinnitus, deafness, Cutaneous 
hypersensitivity 
Renal damage, aplasic anemia, 
agranulocytopenia, neuromuscular
blockade in patients receiving muscle
relaxants or with myasthenia gravis.
 
ISONIAZID
        Isoniazid is still considered to be the primary drug for the 
chemotherapy of tuberculosis and all patients with disease caused by 
isoniazid sensitive strains of the tubercle bacillus should receive the drug 
if they can tolerate it.
Primary mechanism of action of isoniazid is to inhibit the biosynthesis of 
mycolic acids, important constituents of the mycobacterial wall. From 
75% to 90% of dose of isoniazid is excreted in the urine within 24 hours, 
mosyly as metabolites. The main excretory products in human beings are 
the result of enzymatic acetylation( Acetyl isoniazid)and enzymatic 
hydrolysis(Isonicotinic acid).The rate of acetylation significantly alters 
the 
concentrations of the drug that are achieved in plasma and its half life in 
the circulation. Acetylator status is estimated by measuring free and 
total sulpha dimidine in blood and urine.
         Risk factors for isoniazid hepatotoxicity include acetylator 
status,older age and history of severe alcohol intake.
                While the Drug induced hepatotoxicity in initial studies ranged 
from 1 percent to 10 percent recent observations where clinically relevant 
hepatotoxicity was evaluated suggsted that less than 1 percent subjects 
receiving isoniazid for treatment of latent tuberculosis infection 
developed hepatotoxicity.
    
    Jaundice occurs in 0.6% 5,8,9,10 to 1% 11,12.Increased serum 
enzyme levels were noted in 10 -20% of patients 5,13. Byrd et 
al recommended that an elevation of s.enzymes greater than 5 times 
normal should be considered for discontinuation of the drug. Most 
hepatitis occurs within 4 to 8 weeks of therapy. Liver biopsy may show 
bridging necrosis and features of acute hepatitis 14 .
    
                           
                           RIFAMPICIN   
    
             Rifampicin inhibits DNA dependent RNA polymerase of 
mycobacteria and other micro-organisms. Rifampicin is bactericidal for
both intracellular and extracellular micro-organisms. Following 
absorption from the  gastrointestinal tract, rifampicin is eliminated  
rapidly in the bile; and an  enterohepatic circulation ensures. 
Rifampicin 
is distributed throughout the body and is present in effective 
concentrations in many organs and body fluids  including the CSF.
     Hepatitis from rifampicin rarely occurs in patients with normal 
hepatic  function. Elevation of s.bilirubin and alkaline phosphatase levels 
are  characteristic of rifampicin toxicity. Chronic liver disease, 
alcoholism and old  age appears to increase the incidence of 
hepatotoxicity when rifampicin is  given alone or concurrently with 
isoniazid.
   An elevation in serum hepatic enzyme levels occurs in 5-10% of 
patients.15  Clinical hepatitis occurs in 0.6 -2% of patients 8,16  though one 
Indian study shows 7-8% 17Several studies have shown that the incidence 
Of hepatitis in  regimens containing both isoniazid and rifampicin is
approximately 2-4 times  that of isoniazid alone 18. Liver biopsy shows
patchy  cellular abnormality with  marked periportal inflammation.19
15
                                  PYRAZINAMIDE
   Pyrazinamide is the synthetic pyrazine analog of nicotinamide. It 
exhibits  bactericidal activity only at a slightly acidic PH. The target of 
pyrazinamide  appears to be the mycobacterial fatty acid synthase I gene 
involved in mycolic  acid biosynthesis. Pyrazinamide is well absorbed 
orally and is widely  distributed. The drug is excreted primarily   by renal 
glomerular filtration.
  When a dose of 40 – 50mg/kg is administered orally, signs and
symptoms  of hepatic disease appear in about 15% of patients, with 
jaundice in 2% to 3%  and death due to hepatic necrosis in rare instances. 
Regimens employed  currently ( 15 to 30 mg/kg/day) are much safer 20,21. 
In a large Indian study on  hepatic toxicity with short course regimens 
containing rifampicin, isoniazid and  pyrazinamide there was no 
indication that pyrazinamide contributed to the 
development of hepatotoxicity.22 However, in some studies pyrazinamide
was found to be significantly contributed to the development of 
hepatotoxicity  when given along with isoniazid and rifampicin.23,24
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                 ETHAMBUTOL
About 75 to 80% of an orally administered drug is absorbed within in 
24 hours. Three fourths of an ingested dose of ethambutol is excreted 
unchanged in the urine. The drug is excreted by tubular secretion in 
addition to glomerular  filteration . It does not produce hepatotoxicity.
BACTERIAL POPULATIONS AND ACTION OF DRUGS
Special population model, suggested by Mitchison et al  25 for 
explaining the  early bactericidal and sterilizing properties of drugs 
includes :
Population A: Activity growing organisms killed mainly by INH; Other
contribute to this action.
Population B : Semi-dormant organisms inhibited by a acid environment, 
killed mainly by pyrazinamide  because it is active only at ph 5.5 or less.
Population C : Semi-dormant organisms with spurts of activity, lasting 
perhaps a few hours. Killed preferentially by rifampicin because its 
bactericidal  action starts quickly. Organisms may be in neutral or acid 
environment.
Population D : Completely dormant bacilli, unaffected by any drug.
17
DRUG INDUCED HEPATOTOXICITY-MECHANISMS    
    Hepatic biotransformation mechanisms involving oxidative 
pathways,  primarily by way of the cytochrome P-450 enzyme system are 
vital for  rendering the drugs more hydrophilic. Further metabolic steps 
such as  conjugation to a glucuronide, sulphate or glutathione result in the 
formation of  hydrophilic metabolites that are exported into the plasma or 
bile and are  excreted by the kidney or the gastrointestinal tract.26,27 Drug 
induced liver  injury is a common but often unrecognized cause of liver 
damage that  continues to  fascinate and challenge clinicians. 
           Several types of drug induced liver damage have been described.
These  include 1. Idiosyncratic damage,  2. Dose – dependent toxicity; 3. 
Induction   of  hepatic enzymes 4. Drug induced acute hepatitis and  4. 
Allergic reactions,  among others.28 
Idiosycratic reactions are the result of a ‘multihit` process due to the 
succession of unlikely events and are characterized by a variable latency 
period  from the initial time of ingestion of the drug. In the case of some 
drugs such as  acetaminophen, hepatic damage occurs in a dose 
dependent fashion. Induction  of hepatic enzymes by drugs enhances 
18
hepatotoxicity. Allergic reactions 
manifest with fever, lymphadenopathy, rash and severe hepatocyte injury.
CLINICAL SYNDROMES WITH DRUG  HEPATOTOXICITY :
       The following are the clinical syndromes observed in patients with 
drug  induced hepatotoxicity 29:
Abnormal liver function tests in asymptomatic patients
Acute viral hepatitis – like presentation
Acute (fulminant) hepatic failure
Subacute hepatic failure
Acute venous outflow obstruction
Cholestatic hepatitis, obstructive jaundice, chronic cholestasis 
Liver disease with signs of hypersensitivity and / or disease in other 
organs. Auto-immune hepatitis – like injury.
Cirrhosis
Primay hepatic neoplasms.
19
ANTITUBERCULOUS DRUGS AND HEPATOTOXICITY :
        The pathogenesis of hepatotoxicity caused by isoniazid is not well 
understood. Histopathological evidence resembling that of viral 
hepatitis  showing hepatocyte necrosis, ballooning degeneration and 
inflammatory  infiltrates suggests dose related toxicity.30 However lack 
of direct  correlation between serum drug levels and hepatotoxicity 
argues against a  direct toxic effect 31.Given the delayed onset of 
hepatotoxicity, absence of  symptoms usually associated with 
hypersensitivity and no hepototoxicity on  re-challenge in most cases, 
hypersensitivity is considered unlikely.32,33 But  presence of 
eosinophilic infiltrates on liver biopsy and recurrence of  
hepatotoxicity on re-challenge with the drug suggest hypersensitivity 
as a  possible mechanism.33
              Altered profile of antioxident enzymes with increased lipid 
peroxidation indicated that isoniazid and rifampicin induced
hepatotoxicity  appeared to be mediated through oxidative stress.34 
Compared with  isoniazid,   rifampicin hepatotoxicity occurs earlier 
and produces a patchy  cellular  abnormality with marked periportal 
inflammation.35 Rifampicin  induced  hepatitis has been postulated to 
20
occur as a part of systemic allergic reaction  and due to unconjugated 
 hyperbilirubinemia as a result of competition with 
bilirubin for uptake at hepatocyte plasma membrane.35
         The increased risk of hepatotoxicity with isoniazid and rifampicin 
combination has been attributed to the interaction between the 
metabolism of isoniazid and rifampicin. Acetyl isoniazid, the principal 
metabolite of isoniazid is converted to mono acetyl hydrazine. The 
microsomal P450 enzymes convert mono acetyl hydrazine to other 
compounds resulting in hepatotoxicity.36 Rifampicin is thought to 
enhance this effect by enzyme induction.
                       The first human case of a proven hepatotoxic interaction 
between isoniazid and rifampicin has recently been reported by
Askgaard et  al.37 A 35 year old black Somalian patient with miliary 
tuberculosis developed  hepatotoxicity after a few days of treatment 
with isoniazid, rifampicin,  pyrazinamide and ethambutol. On 
withdrawing all the drugs, the liver profile  normalized and remained 
so after isoniazid challenge. Hepatotoxicity  recurred when rifampicin 
was added but it was well tolerated when rifampicin was reintroduced 
without isoniazid.
21
                  In patients receiving a combination of isoniazid, rifampicin 
and pyrazinamide, two patterns of fulminant liver injury have been 
observed. Increased in serum transaminase activity which occurs late 
(usually after one month) has been attributed to pyrazinamide induced 
hepatotoxicity while the early increase in transaminases (usually within 
first  15 days) has been attributed to rifampicin and isoniazid induced 
hepatotoxicity. 
               Asymptomatic increase in AST has been observed in about 
20% of  patients receiving the standard four drug regimen.38  Singh et
al  reported that overall mortality in patients with drug induced 
hepatotoxicity  caused by anti tuberculous therapy was 12% while it 
was 75% in patients  who developed acute and sub acute liver failure.39
DIAGNOSIS OF   HEPATOTOXICITY DUE TO ATT
In a case control study from the AIIMS, New Delhi, Pande et al
assessed the role of several risk factors in the development of anti-
tuberculous treatment induced hepatotoxicity in patients with pulmonary 
tuberculosis.40 The diagnostic criteria for anti-tuberculous treatment 
induced hepatotoxicity were as follows.
22
   One more study by Sharma et al suggests almost the same.
1. Clinical features of icteric hepatitis (anorexia, nausea and jaundice)
2. Serum aspartate and alanine transaminase levels greater than 150 
U/L on more  than 3  occasions  or  greater  than 250 U/L on one 
occasion.
3. Serum total bilirubin greater than 1.5 mg/dl and 
4. Absence of serological evidence of viral hepatitis. 
           The authors reported that the latency period between start of anti-
tuberculous treatment and development of hepatotoxicity in the cases was
4-9 days and in most cases hepatotoxicity was evident within 3 months of 
start of  treatment
         In a retrospective study of 519 patients receiving isoniazid, 
rifampicin and pyrazinamide from Germany hepatotoxicity was observed
in  11% of patients. 41
     In another retrospective study of 456 patients receiving 
isoniazid, rifampicin, pyrazinamide, streptomycin or ethambutol from 
Argentina, signs of liver injury were found in 9.9% of patients.42
23
MANAGEMENT  
      Idealy treatment should be individualized according to the body 
weight and co-morbid illness present in the patient. Whenever feasible, 
baseline liver function testing must be done. When drug-induced 
hepatotoxicity is suspected, the  patient receiving anti-tuberculosis-
treatment should be systematically  investigated for other causes such as 
viral hepatitis. Consensus guidelines for  the management of patients with 
anti-tuberculosis treatment-induced  hepatotoxicity are yet to be evolved. 
The Joint Tuberculosis committee of The British Thoracic Society 
recommendations43 and the recent guidelines published  by the American 
Thoracic society, Centers for Disease Control and Prevention 
and the Infectious Diseases Society 38 form the basis for the diagnosis and 
management principles listed below.
Once the diagnosis of drug induced hepatotoxicity is established, it is 
essential to first stop all potentially hepatotoxic drugs till complete 
clinical and  biochemical resolution of hepatotoxicity occurs. In the 
interim period, at least  three non-hepatotoxic drugs such as ethambutol, 
streptomycin and quinolones  such as levofloxacin or ofloxacin or 
24
ciprofloxacin can be used after appropriate  evaluation of renal function 
and visual acuity.
After complete resolution of transaminases, most anti-tuberculosis 
drugs  can be safely restarted in a phased manner. The British Thoracic 
Society  guidelines 43 suggested that the first-line drugs can be 
reintroduced sequentially in  the order isoniazid, rifampicin and 
pyrazinamide with daily monitoring of the  patients’ condition and liver 
function. Isoniazid should be introduced at 50  mg/day, gradually 
increasing sequentially to 300 mg/day over two to three days 
if it is well tolerated and continued thereafter. After a further period of 
two to  three days, rifampicin is introduced at a dose of 75 mg/day 
increasing to 300  mg/day after two to three  days and then increased to 
450 mg (<50 kg) or 600  mg (>50 kg) as appropriate for the patient’s 
weight after a further period of two  to three days. If this is tolerated, it is 
then continued. Finally, pyrazinamide can  be added at 250 mg/day 
increasing to 1000 mg after two to three days and then  to 1500 mg (<50 
kg) or 2000 mg (>50kg) as appropriate for the patient’s  body  weight. If 
these drugs are well tolerated, they are continued and the alternative 
drugs introduced temporarily can be withdrawn.
25
         According tothe American Thoracic society, Centers for Disease 
Control and  Prevention and the Infectious Diseases Society  guidelines 38 
the reintroduction  protocol is somewhat different. According to these 
guidelines, suspected anti-tuberculosis drugs can be started one at a time 
once the transaminase levels return to less than two times the upper 
normal. Rifampicin is to be restarted first. If the liver functions remain 
normal after one week, isoniazid can be  added to the regimen. If the liver 
functions remain normal after one week, then  pyrazinamide is added. If 
there is recurrence of symptoms or deterioration of  liver functions, the 
last added drug should be stopped.
DRUG RE-INTRODUCTION
The re-introduction of anti-tuberculosis drugs has seldom been 
systematically studied and a great deal of controversy exists regarding 
sequence in which the drugs are to be reintroduced, whether the 
reintroduction  should be done in full dosage or in gradually escalating 
dosages. 
    Usually, it is possible to safely re-introduce the same drugs that have 
been  implicated in the causation of drug induced hepatotoxicity in a 
majority of the  patients. Review of published literature suggests that, the 
recurrence rate of  hepatotoxicity when antituberculosis drugs are re-
introduced was less than 7  percent 39 though a recurrence rate of more 
26
than 25 per cent has been cited in  some studies.44 In a study from New 
Delhi, Singh et al 40 reported that, after  resolution of hepatotoxicity, 
reintroduction of isoniazid and rifampicin was  possible in 41 of 44 
patients suggesting that the recurrence rate of  hepatotoxicity on 
reintroduction was 6.8 per cent.  In the study reported by  Telman et al 45 
55 of the cohort of 1036 patients (5.3%) developed hepatotoxicity. 
      Treatment was re-introduced in 48 patients and successfully completed in 45 
patients indicating that the recurrence rate f DIH on reintroduction of  antituberculosis 
treatment was 6.3 per cent.
In a study from Copenhagen  61 of the 752 patients with tuberculosis 
(8%)  developed hepatotoxicity 44. Recurrence of hepatotoxicity was 
observed in 16 of  these 61 patients (26.2%) on reintroduction of 
antituberculosis treatment and  they required a modified regimen. 
Multicentric prospective randomized studies  with a large sample size are 
required to clarify these issues.
27
RISK FACTORS
     Advanced age, female sex, hypoalbuminemia, high alcohol intake, 
acetylator  phenotype,  hepatitis  B  &C  viruses,  HIV,  malnutrition  and 
extensive  disease were found to be the risk factors for the development 
of hepatotoxicity.40,42
ACETYLATOR STATUS :
       Because acetyl isoniazid formation occurs in larger amounts in 
rapid  rather than slow acetylators it was suggested that rapid 
acetylators are more  prone to hepatotoxicity.46 However the 
observations that both rapid and slow  acetylators excreted similar 
proportions of mono acetyl hydrazine suggested  that, in rapid 
acetylators, the more rapid conversion of acetyl isoniazid to 
mono acetyl hydrazine is compensated by its more rapid conversion to 
di acetyl hydrazine and its excretion contesting this theory.47,48 Other 
reports  have suggested that products of hydrolysis rather than 
acetylation are the critical toxic metabolites of isoniazid. A small 
portion of isoniazid is directly  hydrolysed and the proportion of drug 
metabolised through this direct  pathway is greater in slow acetylators 
than in rapid acetylators.49 Studies by  Sharma et al associates showed 
28
that the hepatotoxic action of metabolites of  isoniazid is due to the 
hydrazine formed from isoniazid.50 Rifampicin induces  the 
metabolism of isoniazid by isoniazid hydrolase resulting in the 
formation  of isonicotinic acid and hydrazine.51 It has been suggested 
that concomitant  administration of rifampicin and isoniazid could 
result in increasing levels of  hydrazine and this could provoke 
hepototoxicity especially in slow  acetylators.52 This hypothesis is 
supported by the finding of increased hepatotoxicity in slow 
acetylators. Prema Gurumurthy et al  53 states that there 
is no relation especially in south Indian patients with relation to 
acetylator  phenotype and hepatotoxicity.
ANATOMY OF LIVER
   It is the largest organ of the body, weighing 1200 to 1500 gms. It 
is unique for its dual blood supply. Portal vein provides 60 to 70% of 
hepatic  blood flow and the hepatic artery the reminder. Liver infarctions 
are rare due to  dual blood supply.
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functions of the liver 
      The functions of the liver are many and varied. Hence there is no 
single biochemical test which can reflect all the functions of the liver. 
Few  functions of the liver are given below.
1.Synthetic and metabolic function.
2. Detoxifies and excretes the products of metabolism.
SYNTHETIC FUNCTION :
The hepatocytes synthesize the following
1. Plasma Proteins, except Immunoglobulin and complement.
2.  Most  coagulation  factors,  including  fibrinogen,  factor  II 
(Prothrombin), V, VII, IX, X, XI, XII & XIII ,of these II, VII, IX 
and X are synthesized in the presence of vitamin K :
3. Lipo proteins – VLDL & HDL
4. Primary bile acids.
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LIVER FUNCTION TESTS
Few liver function tests are given below :
A. Tests indicating liver cell damage.
1. Serum  Aspartate  Amino transferase (AST / SGOT)
2. Serum Alanine amino transferase (ALT / SGPT)
B. Tests indicating biliary tract involvement.
1. Serum alkaline phosphatase
2. Gamma glutamyl transferase
3. Serum 5’ nuceotidase.
C. Tests indicating impaired hepato cellular function.
1. Serum albumin
2. Coagulation factors.
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D. Other Tests
1. Viral markers – Igm & IgG anti HAV antibody, Igm & IgG 
anti HEV antibody ,HBsAg, anti HbsAg antibody ,Anti HCV 
antibody
2. Alpha feto protein.
3. Circulating auto antibodies
4. Ultrasound abdomen – Non invasive imaging techniques like 
ultra  sonogram  is  useful  to  find  out  cystic  liver  mass, 
cirrhosis   and biliary calculi. Of limited use in drug induced 
hepatitis.
5. C.T. Scan Magnetic resonance Imaging  -   Architecture of 
the    cells can be made out. Functional alterations cannot be 
made out.
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COMMONLY USED LIVER FUNCTION TESTS
Table 3.Normal values commonly used liver function tests 54
S.No Tests Normal Range Value
1. Bilirubin  - Total
                 - 
Conugated
0.3 – 1 mg/dl
  <0.3 mg/dl 
Diagosis of Jaundice, 
assess 
severity.
Gilbert’s disease, 
hemolysis.
2. Alkaline 
Phosphatase
35 – 130 IU/L Diagnosis of Cholestasis
hepatic infiltrations.
3. Aspartate 
transaminase
(AST / SGOT)
5 – 40 IU/L Early diagnosis of 
Hepatocellular
disease; Follow progress.
4. Alanine 
Transaminase
(ALT / SGPT)
5 –35 IU/L ALT relatively lower than 
AST in alcoholism.
5. Albumin 35 – 50 g/L Assess Severity
6. Prothrombin Time 
(PT)
(after vitamin K)
12 – 16 S Assess severity.
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BILIRUBIN
Hemoglobin released by destruction of aged cells is broken down into  
globin and heme. The heme is further broken down into iron and 
bilirubin.  Bilirubin attaches to serum albumin and is transported to the  
liver where it is  taken up. In the liver bilirubin detaches from the  
albumin and is conjugated to  glucuronide by glucuronyl transferase. The 
conjugated bilirubin is water  soluble and can be excreted by the kidney.
  The conjugated bilirubin is excreted through the bile canaliculi and 
reaches the intestine where it is converted to stercobilinogen and 
urobilinogen by the  intestinal bacteria. About 70% undergoes entero-
hepatic circulation. The  unabsorbed stercobilinogen gives brown colour 
to the faeces. Circulating urobilinogen is carried to the kidney for  
excretion in the urine as urobilinogen.
    The serum bilirubin may be increased in both cholestatic and 
hepatocellular disease with an associated rise in liver enzymes. In these  
cases  the bilirubin is predominatly conjugated. As isolated rise in serum 
bilirubin (without enzyme elevation) may be familial or due to hemolysis.  
Serum  bilirubin estimations are based on the Van den Bergh reaction.
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Aminotransferases
    Aspartate transaminase (AST; Serum Glutamic oxaloacetic 
transaminase  or SGOT) is a mitochondrial enzyme present in large 
quantities in heart, liver,  skeletal muscle and kidney, and  the serum level 
increases whenever these are acutely destroyed, presumably due to 
release from damaged cells.
 Alanine transaminase (ALT; Serum Glutamic Pyruvic transaminase 
or SGPT) is a cytosolic enzyme also present in liver. Although the 
absolute amount is less than SGOT, a greater proportion is present in liver 
compared  with heart and skeletal muscles. A serum increase of SGPT is 
therefore more  specific for liver damage than SGOT.
Transaminase determinations are useful in the early diagnosis of viral 
hepatitis. Measurement must be made early as normal values may be 
reached  within a week of the onset. Routine screening may show 
unexpectedly raised  aminotransferase levels. These are often due to 
obesity, diabetes mellitus,  alcohol abuse, hepatic drug reaction or 
circulatory failure.
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     A high ratio of SGOT to SGPT (greater than two) may be useful in 
diagnosing alcoholic hepatitis and Cirrhosis. This is  not due to 
hepatocyte  damage but to pyridoxal 5- phosphate (vitamin B6) 
deficiency. The commonest causes of raised AST (SGOT) being greater 
than 10 times the upper limit of  normal in a general hospital are hepatic 
hypoxia and calculous bile duct  obstruction. Viral and drug hepatitis are 
rare.
       Some workers have suggested that if the transaminase levels are 
less than five times the upper normal limit, the toxicity was considered 
mild. When the transaminase levels were increased to five to ten times 
the normal, the toxicity was considered to be moderate. Elevation of 
transaminase more than 10 times the upper normal limit suggests severe 
toxicity.38
ALKALINE PHOSPHATASE :
The level of alkaline phosphatase rises in cholestasis and to a lesser 
extent  when liver cells are damaged. Serum hepatic alkaline phosphatase 
may be distinguished from bony phosphatase by fractionation into 
isoenzymes, but this  is not routinely carried out. An isolated rise in 
alkaline phosphatase may be of  intestinal  origin.55 A rise in Gamma – 
glutamyl transpeptidase confirms the likely source of alkaline 
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phosphatase as being hepato biliary.
ALBUMIN :
     Albumin is mainly synthesized in liver. About 10 gm of albumin is 
synthesized by the normal liver daily, where as those with cirrhosis can 
only  synthesize about 4gm. In liver disease, the fall in serum albumin 
concentration  is slow, as the half life of albumin is about 22 days. A 
patient with  decompensated cirrhosis would be expected to have a low 
level. Hypoalbuminemia is also found in nephrotic syndrome, 
malnutrition and  pregnancy.
PROTHROMBIN TIME :
    This is the time taken for platelet poor citrated plasma to clot after 
adding calcium and tissue (brain) Thromboplastin. This is an important 
screening test for defects of the extrinsic and common pathways of 
coagulation  since the intrinsic pathways are bypassed by adding tissue 
factor and calcium. The prothrombin time before and after 10mg vitamin 
k given intravenously is the most satisfactory test for a coagulation defect 
in patients with hepato-biliary  disease. Prolongation indicates not only 
deficiency of the prothrombin complex but also factors XI and XII.
histology of liver 
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      Lobules consist of a central tributary of the hepatic vein and at the 
periphery a portal tract containing the bile duct , portal vein radicle and 
hepatic  artery branch. Columns of liver cells and blood containing 
sinusoids extend  between these two systems. Acini, the functional unit of 
liver, is centered on  the portal triad. These interdigitate, mainly 
perpendicularly, with terminal  hepatic veins of adjacent acini.
Liver biopsy
      Liver biopsy is now an accepted, safe, invasive procedure in most 
hospitals to investigate liver disease. It samples accurately in all diffuse 
anatomic lesions and in majority of focal lesions.                       
      The Menghini needle obtains a specimen by aspiration. Most 
commonly used puncture biopsy needle which grasps the tissue within 
the cannula is  Vim  Silverman needle. The sheathed Trucut needle is a 
modification of  Vim  Silverman needle. Other methods are guided 
biopsy ,biopty gun method  and  transjugular liver biopsy.
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INDICATIONS 57
        Drug induced hepatitis, Chronic hepatitis, Cirrhosis,  Liver 
disease in  the alcoholic, Intra hepatic cholestasis, Infective conditions, 
Storage  diseases, Post hepatic transplantations, Space occupying 
lesions,  unexplained hepatomegaly or enzyme elevations.
CONTRA INDICATIONS 
     1. Abnormalities of blood coagulation and thrombocytopenia < 50,000 
         cells/cu.mm.
  2. Hydatid cyst of liver.
 3. Sepsis
 4. Haemangioma.
TECHNIQUE OF PUNCTURE:
       Sedation is not given routinely as it may interfere with the 
patient’s co-operation. In supine position after adequate local 
anaesthesia the needle  with 3 ml of sterile solution is inserted in the 8th 
or 9th intercostal space in  mid-axillary line at the end of expiration 
with the patient breathing quietly. 2ml of solution are injected to clear 
the needle  of any skin fragments.  Aspiration is now commenced and 
39
maintained with the patient holding his breadth in expiration, the 
needle  is rapidly introduced perpendicularly to the  skin into the liver 
substance and extracted. The tip of needle is now placed  on sterile 
paper and some of the remaining saline flushed through the needle  to 
deposit the biopsy gently into the paper. The tissue is transformed into 
fixative.
COMPLICATIONS :
          Complications are reported in 0.06 – 0.32% patients with 
mortality of  about 0.1%.56 Complications range from pain in the site of 
puncture,  mild oozing due to hemorrhage, bile peritonitis, perforation 
of abdominal  viscera, pneumothorax and precipitation of hepatic 
coma.
40
MATERIALS AND METHODS
         Patients were selected from amongst those who registered in the 
tuberculosis clinic of coimbatore medical college hospital, Coimbatore 
from  January 1st 2005 to the end of June 2005 and they were followed 
upto December 2005.
ELIGIBILITY CRITERIA
1. Patients above 18 yrs with adequate evidence of pulmonary 
tuberculosis  were chosen.
2. Only sputum positive cases were selected.
3. Patients coming from within and near by nearly areas of coimbatore 
were  selected to minimize the dropouts.
EXCLUSION CRITERIA
1. Patients who either had been on ATT previously or were on ATT at 
the  time of the registration in the TB clinic.
2. Sputum smear negative patients.
3. Previous history of jaundice.
4. Pregnant women.
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5. Those in whom baseline enzyme levels were more than upper limit 
of  normal.
6. Patients suffering from any other diseases like diabetes, 
hypertension  and cardiac failure.
7. Patients on chronic medication for any other diseases.
PRE TREATMENT EVALUATION :
       Patients were well informed and consent was taken from the 
patients prior to their enrolment in the study and their compliance 
solicited. They  were advised not to stop the prescribed medications for 
any reason on their own. They were asked to report immediately if any 
adverse symptoms were noticed such as nausea, vomiting, loss of 
appetite, yellowish discoloration of  skin and mucous membrane. The 
details were recorded in a specially prepared proforma, a copy of 
which is annexed.
           The following investigations were performed before starting 
chemotherapy in patients of newly discovered pulmonary tuberculosis.
1. Hb%
2. Platelet Count
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3. Serum Proteins – Total
        -Albumin
4. S. Bilirubin – Total
                             -Direct
5. Serum alkaline phosphatase (SAP)
6. SGOT 
7. SGPT
8. Prothrombin time
9. Chest X-ray PA View.
TREATMENT
        The patients were started on category I regimen under Revised 
National Tuberculosis Control Program containing  isoniazid, rifampicin, 
Pyrazinamide, Ethambutol . The details  of the dosage is given below. All 
drugs are given three times a week.
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INITIAL PHASE
Isoniazid, Rifampicin, Pyrazinamide & Ethambutol –For 2 months
CONTINUATION PHASE
Isoniazid, Rifampicin-For 4 months
DOSAGE OF DRUGS
Isoniazid -300 mg.
Rifampicin – 450 mg (600 mg for patients > 50 kg)
Pyrazinamide – 1.5 gm (2 gm for patients > 50 kg)
Ethambutol – 800 mg.
LIVER FUNCTION TESTS :
Patients liver function was assessed by measuring S. Bilirubin, SAP, 
SGOT, SGPT, S. Proteins  and prothrombin time.
The liver function tests were done prior to drug treatment and then at 
1st, 2nd,  4th, 8th, 12th,16th , 20th and 24th weeks of treatment.
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PROCEDURE :
        Serum bilirubin was estimated according to the method described 
by  Varley SGOT and SGPT  were estimated by the method described by 
Chyne.  Alkaline phosphatase and serum protein were estimated 
according to the methods described by Wootten and Reinhold 
respectively.
EVALUATION DURING THERAPY :
            Patients were given medication on alternate days during the 
initial phase and for one week during continuation phase. Every effort 
was  made to ensure the compliance of the patient. Minor symptoms 
were treated symptomatically. Patients with major symptoms were 
hospitalised.  Data collected during these reviews included.
1. Drug taken
2. Any adverse symptoms with reference to liver function.
3. Liver function tests at 1st, 2nd, 4th, 8th, 16th, 20th and 24th week of 
      treatment.
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        Patients who showed the following features are considered 
significant. 40 Such patients were grouped separately and monitored 
clinically and  Bio-chemically every week
1. More than a five fold (> 250 IU/L) elevation of serum enzymes 
(AST,   ALT) or > 150 IU/L on more than 3 occasions and / or 
2. S. Bilirubin > 1.5 mg and /or.
3. Clinical features of icteric hepatitis 
 DROP OUT FROM THE STUDY :
          These patients who were irregular in their treatment were 
grouped  separately. Among those who did not take the drugs for more 
than 4 weeks continuously were dropped.    Among the 108 patients 
enrolled in the study, the follow up was given below.
1st week – 107 patients
2nd week – 107 patients
4th week – 106 patients
8th week – 104 patients
12th week – 100 patients
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16th week – 98 patients
20th week – 95 patients
24th week – 95 patients
     Total number of dropout was 13 patients and none of them had any 
adverse reactions.
ADVERSE DRUG REACTIONS :
          Serum enzymes are elevated in 13 patients and in these group 
serum bilirubin was elevated in 5 patients. In these only 2 patients 
developed nausea, vomiting, anorexia, yellowish discoloration of urine 
and conjunctiva. Increase in serum enzymes are noted as follows: 4 
patients on  1st week, 6 patients on 2nd week, 3 patients on 4th week. 
Increase in serum  bilirubin are noted in 2 patients on 1st week and 2 
patients on 2nd week and 1  patient in 4th week. Among the patients who 
developed jaundice 1 patient  was on 1st week and 1 patient on 4th 
week. 
         Only clinical and laboratory monitoring was done in 
asymptomatic  patients. In symptomatic patients all drugs were 
withdrawn and liver biopsy  planned. Out of 2 symptomatic patients 
only 1 patient gave consent. After 3  doses of vitamin k, liver biopsy 
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was carried out. Under local anaesthesia using trucut needles liver 
biopsy done. Liver bits obtained were sent for histopathological 
examination in formalin solution and stained with H and E 
stain and the results are given below.
           Biopsy from 52 year male patient showed bridging necrosis and 
multilobular necrosis. ATT was stopped in both symptomatic patients. 
LFT  returned to baseline in 2 weeks. Then drugs were started as 
suggested by the  British thoracic society guidelines. Both patients 
tolerated the drugs well and  continued till the end of treatment period.
DROP-OUTS :
       In patients on ATT, various studies showed a drop-out from 10 to 
40% due to various reasons like lack of literacy, adverse drug reaction, 
sense of  well being, social problems and rarely migration. In our study, 
follow-up of the  defaulters showed drug adverse reactions are not the 
cause of dropouts. Though  we selected patients in and around coimbatore 
and patients were well informed about the study, we had a drop out of 13 
patients from the initial of 108 patients. When the patients in spite of 
reminder cards and calls not responding  and who stops taking treatment 
for > 4 weeks dropped from the study.
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OBSERVATIONS
1. Total patients selected for study – 108.
2. Dropout during treatment – 13
3. Total patients completed full course of Treatment 95 patients.
      Males – 49 patients ;Females – 46 patients
4. Age group –   20 – 66 years.
5. Incidence of Drug Induced Hepatotoxicity in coimbatore population 
who  are on category I, RNTCP, 4 drug regimen is 2.1%. Male : 
Female ratio is approximately  1:1
6. Asymptomatic elevation of serum enzymes in 11 patients (11.6%) 
     male : female ratio =1:1.9
7. Onset of symptoms is between 1-4 weeks after starting ATT.
8. Withdrawal of the drugs produced complete recovery.
9. Hepatotoxicity confirmed by liver biopsy in 1 out of 2 patients who 
      developed clinical hepatitis.
10. Predisposing factors : Old age, Malnutrition, chronic alcohol 
intake,  extensive disease states like  cavitary tuberculosis.
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11. Re-introduction of drugs: Both patients who developed Drug 
Induced  hepatotoxicity tolerated well on drug challenge and the 
same regimen continued.
12.Follow up drop outs : No patients developed adverse drug reactions.
SEX :
  Total No. of males and females completed ATT
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ASYMPTOMATIC HEPATITIS
Table 4 :
AGE GROUP OF PATIENTS : 
Age Group 
(Years)
Male Female Total
20 – 20 11 13 24
30 – 39 16 12 28
40 – 49 10 6 16
50 – 59 8 10 18
60 – 69 4 5 9
Total 49 46 95
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AST / ALT ELEVATION IN PATIENT’S ON ATT
Table : 5
ELEVATION OF SERUM ENZYMES & AGE GROUP / SEX
Age 
Group
Clinical
Hepatitis
Sub Clinical Hepatitis
Total
Percentag
e in total 
patients 
Male Female
20-29       -        2       -      2    8.3%
30-39       -        -      3     3   10.7%
40-49       -        1      2     3   18.8%
50-59 1(M) 
52Years
       1      1     3    16.7%
60-69 1(FM)
63Years
       -       1     2     22.2%
TOTAL     2       4       7     13        -
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SAP ELEVATION
SERUM BILIRUBIN
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Table : 6
 INITIAL ELEVATION OF SERUM ENZYMES, SERUM 
BILIRUBIN  AND CLINICAL HEPATITIS-WEEK WISE
Weeks No. of
Patients 
on 
Study
Serum
ALT
Serum
AST
SAP S. 
Bilirubi
n
Clinical
Hepatiti
s
0 108 0 0 0 0 0
1 107 4 4 4 2 1
2 107 6 6 6 2 0
4 106 3 3 3 1 1
8 104 0 0 0 0 0
12 100 0 0 0 0 0
16 98 0 0 0 0 0
20 95 0 0 0 0 0
24 95 0 0 0 0 0
TOTAL    - 13 13 13 5 2
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Table : 7 
 DROP OUTS
Male Female Total Percentage
Initial 57 51 108
Dropout 8 5 13 12%
Completed 
the
Course
49 46 95 88%
TABLE : 8
DISEASE STATUS AND HEPATOTOXICITY
Lesion No. of
Patients
Clinical
Hepatitis
Sub clinical
Hepatitis
Cavitary Lesion 6 2 1
Non Cavitary 
Lesion
89 - 10
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DISCUSSION
      In this study of 108 patients of sputum positive pulmonary 
tuberculosis all are administered category I regimen of RNTCP i.e 
Isoniazid, Rifampicin, Pyrazinamide and Ethambutol for first 2 months 
followed by isoniazid and rifampicin for next 4 months. All are given in 
thrice weekly  basis.
Total number of patients taken : 108 Patients
Drop out of Patients : 13 patients
Regularly followed till the end of treatment : 95 patients
Out of this, male patients – 49 and female patients are 46.
Male : Female ratio is approximately 1:1
AGE 
   The age group of the patients ranged from 20 – 67 yrs  In our study, 
clinical  hepatitis occurred in old age patients only  (52 years  & 63 yr ) 
Studies from  Pande et al 40 also shows that increasing age is associated 
with more  hepatotoxicity.  Subclinical hepatotoxicity were noted in the 
range of 26-61  yrs. No of patients had subclinical hepatotoxicity is 11. 
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(Male : Female ratio  group) than in  younger age group (8.3% in 20-29 
yr age group)
SEX 
  Clinical hepatitis occurred in 1 male and 1 female patient. Ratio is 
approximately 1:1. Subclinical hepatitis occurred in 4 male and 7 female 
patients. Male : Female ratio is 1:1.9.
    Many studies showed female patients are more prone 40,42 but in our 
study  there is no difference in clinical hepatitis. This can be explained by 
our small  study and only 2 patients developed clinical hepatitis. 
Subclinical  hepatotoxicity in our study is more common in female 
patients and this is in  accordance with many studies .40,42
NUTRITIONAL STATUS :
    38 males and 30 females had normal nutritional status and 11 males 
and 16 females had mild malnutrition. (S. Albumin <3mg).Krishnaswamy 
says  that under nutrition contributes to drug toxicity by various 
mechanisms.58 
     Toxicity and over dosage is much more likely to occur with even 
normal  dosage of medicine in the presence of low serum albumin.
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      In our study, both patients who developed clinical hepatitis had 
mild  malnutrition. Subclinical hepatotoxicity developed even in normal 
individuals.
DISEASE STATUS :
    Advanced disease predisposes to hepatotoxicity. 40,42
   In our study patients who developed clinical hepatitis had cavitary 
lesions,  subclinical hepatotoxicity occurred in patients of both cavitary 
and noncavitory  patients.
ALCOHOL INTAKE
       History of Alcohol intake predisposes patients to hepatotoxicity 
than  no history of alcohol intake. In our study one patient out of two with 
clinical  hepatitis gives history of alcohol intake.
VIRAL MARKERS :
      None of the patients found to be positive for HBsAg or anti HCV 
antibody in our study. Hepatitis B virus ,Hepatitis C virus patients are 
more  prone to develop drug induced hepatotoxicity.40,42
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COMBINATION CHEMOTHERAPY AND HEPATOTOXICITY
  The incidence of hepatotoxicity due to combination chemotherapy 
ranges  from 1% to 39%
The following is a list of incidence by some workers.
1. Parthasarathy et al 59 - TBM 16-39%
                    -  PT 2-8%
2. Schberg et al 41 -11%
3. Devoto  et al 42          -9.9%
4. Steele et al 8          -2.6%
5.    Dossing et al 44             - 8%
6.    Kamat et al  from Bombay 60 -18%
7.    Sivaraman et al  61           - 7%
In our study it is 2.1%
The Tuberculosis Research centre, Chennai (1983) has published the 
first report on short course chemotherapy(SCC) on South Indian 
patients.62 All patients in this study received INH and pyrazinamide and 
2/3rd of them also  received rifampicin. Hepatitis occurred in 17 (2.5%) 
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of 693 patients.In addition, 14 (2%) had transient elevation of 
aminotransferases detected during  routine monitoring. It was noted that 
eight patients who developed hepatitis during first two months were from 
rifampicin series.   Lower incidence in our study is probably due to lower 
duration of  treatment, lower dosage used  than preciously and  may be 
because of   intermittent regimen.
ASYMPTOMATIC HEPATITIS
The frequency of asymptomatic, self-limited elevations of enzymes, 
raises  the question of whether the drugs should be stopped when an 
elevated level is encountered and if so, at what levels they should be 
stopped. Moreover, the  hepatic reactions may develop with such rapidity 
that even weekly estimations  of serum enzymes may not provide 
sufficient warning. Mild transient and  symptom less increases in serum 
hepatic enzymes are usual during early weeks  of treatment whatever the 
drug regimen and on no account should treatment be  interrupted or 
altered because of these increases . Judgement  of  withhold or continue 
drugs should be based on clinical grounds rather than on  laboratory 
parameters alone in a given case.
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ONSET OF HEPATOTOXICITY :
     Increase in Serum transaminase activity which occurs later (usually 
more than one month) has been attributed to Pyrazinamide while early 
increase in  serum transaminase (usually < 15 days) has been attributed to 
Isoniazid &  Rifampicin. Isoniazid toxicity is more common in first few 
weeks of therapy.  In our study both clinical and sub clinical hepatitis 
occurred  in < 4 weeks.
SYMPTOMATIC HEPATITIS :
Incidence of drug induced hepatitis in various studies were listed 
above.  Generally asymptomatic hepatitis is more common than clinical 
hepatitis. Symptoms are not reliable always but Parthasarathy  et al 
59states that  hepatitis nearly always associated with jaundice.
      In our study both patients with clinical hepatitis had jaundice and 
bio-chemical elevation of serum transaminases above 5 folds. Elevation 
of SAP  was also seen in these patients though it was only 2-3 fold rise S. 
Bilirubin was  raised in 5 patients, but > 4 mg% was seen only in 
symptomatic patients. After  withdrawing the drug all the liver function 
tests returned to normal level. (In 4  weeks in 1 patient and in 2 weeks in 
another patient).
61
WITHDRAWAL OF DRUGS :
       Some workers says patients who developed symptomatic hepatitis 
does  not warrant withdrawing of all the drugs.63 But since there are a lot 
of reports of  fulminant hepatic failure and death, withdrawal of all the 
drugs till the elevated  serum enzyme level decline to normal level is 
advisable.
     In our study, withdrawal of all the drugs was done in both 
symptomatic  patients.
DRUG RE-INTRODUCTION :
      Drug re-introduction is a must, because all are very effective 
bactericidal  drugs. There are 2 schools of thought in drug re-
introduction.
      We followed the guidelines prescribed by the British thoracic 
society. 43   None of the patients developed any reaction on drug re-
introduction and the  same drugs prescribed and patients were discharged 
with the advise to get  admitted immediately if they develop any 
symptoms of hepatitis.
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CONFIRMATION OF HEPATOTOXICITY DUE TO DRUGS :
        Both the patients who developed symptoms of hepatitis were 
screened  for hepatitis B antigen, anti HCV antibody and found to be 
negative. Tests for  Hepatitis A, D & E viruses could not be done due to 
lack of facilities.
       Since the patients were only on prescribed medications ie 
hepatotoxic  anti tuberculous drugs, it was concluded that the hepatitis is 
due to drug  toxicity. Liver biopsy specimen correlated with clinical 
symptoms and bio- chemical test results. Hence drug induced hepatitis 
was confirmed.  As Kumar  states endemicity of viral hepatitis may not 
have chance in  this study.
DROPOUTS :
       In various studies the dropout  ranges from 16 to 70%. In our study 
drop out was 13.6%. None of them had any adverse reactions.
PREVENTION OF DRUG INDUCED HEPATITIS :
       We cannot predict which patient will develop hepatotoxicity but 
susceptibility is more in patients of older age group, women, malnutrition 
and  extensive disease states.
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     High protein diet, abstinence from alcohol and smoking, good 
supportive  medication with vitamins like vitamin B6, Vitamin C will 
reduce the  incidence. Well educated patients and skilled, alert treatment 
supervisor can  reduce hepatotoxicity, fulminant hepatitis and its 
complications.
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CONCLUSION
1. Though drug induced hepatotoxicity occurred in 2.1% of the 
patients this  is significant.
2. Asymptomatic rise in serum enzymes are noted in 11.6% of 
patients.  This is reverted back to normal before the end of 
treatment.
3. Patients with malnutrition, old age and advanced pulmonary 
tuberculosis   were susceptible to drug induced hepatotoxicity.
4. Patients who had clinical signs and symptoms of hepatitis showed 
histopathological changes in the liver. So it is justified in doing liver 
biopsy in patients with drug induced hepatotoxicity in the presence 
of clinical symptoms and signs or marked elevation of serum 
transaminases, since it is a simple, reliable, relatively safe 
procedure.
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SUMMARY
      In this study of 108 patients of new sputum positive patients 57 
were males and 51 were females. The age group ranged from 20-67. Out 
of 95  patients who completed treatment 11 patients had asymptomatic 
rise in serum  enzymes with male: female ratio of 1:1.9. Two patients had 
symptomatic  hepatitis with male : female ratio of 1:1 in the  ages of 
52year and 63 year.  Patients in older age group, mild malnutrition and 
cavitary disease only had  symptomatic hepatitis.
   Needle biopsy of liver conformed drug induced hepatotoxicity in 1 
patient as the other did not consent for liver biopsy. Re-introduction of 
drugs  done in the patients gradually after s. enzymes reverted back to 
normal levels.  Both patients tolerated well on drug re-challenge. 
Patients closely monitored  and discharged with the advice to get admit 
immediately if there any symptoms  of hepatitis.
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PROFORMA :
Evaluation of liver functions in patients on anti tuberculous therapy.
Name : Age : Sex :
Address :
Case No :
TB O.P. No :
Diagnosis :
Regimen :
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S.
No. HISTORY
Before 
Treatment
During 
Treatment(weeks)
1 2 4 8 1
2
1
6
2
0
2
4
1 Anorexia
2 Nausea
3 Vomiting
4 Jaundice
5 Epigastric Pain
6 Diarrhea
7 Clay stools
8 Fever
9 Bleeding Tendencies
10 Skin Rashes
S.
N
o.
EXAMINATION Before Treatment
During 
Treatment(weeks)
1 2 4 8 1
2
1
6
2
0
2
4
1 Pulse
2 BP
3 Temperature
4 Resp. Rate
5 Weight
6 Built & nutrition
7 Anemia
8 Jaundice
9 Skin Lesions
10 Hepatomegaly
11 Tenderness in Right 
Hypochondrium
12 Fluid Thrill
13 Shifting dullness
14 Auscultation
15 Miscellaneous
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S.
N
o.
INVESTIGATIONS
Before 
Treatmen
t
During 
Treatment(weeks)
1 2 4 8 1
2
1
6
2
0
2
4
1 HB%
2 Platelet Count
3 Prothrombin Time
4 Urine – Bile Salt
          - Bile Pigments
         - Urobilinogen
5 SGOT (AST)
6 SGPT (ALT)
7 SAP
8 S. Bilirubin  - Total
                    - Direct 
9 S. Proteins  - Total
                   - Albumin
10 Chest X-ray PA View *
11 Viral Markers** - HBsAg 
-                       - Anti HCV 
antibody
12 Ultrasound Abdomen#
13 Liver Biopsy#
14 Others
* -Only during the initial evaluation 
**-On initial evaluation and if they develop hepatitis
#- Only for symptomatic hepatitis patients.
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